Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, has appointed Andrew Sandham executive chairman.This follows the …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

